Zanubrutinib with R-CHOP for newly diagnosed p53-positive DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years old
- Newly diagnosed with diffuse large B-cell lymphoma (DLBCL) and have not had treatment yet
- Your lymphoma cells show a high amount of p53 protein (at least half of the cells)
- You have at least one tumor or lymph node that can be measured on a scan
- Your blood counts and liver, kidney, and heart function are within certain limits (your doctor will check this)
- No active infections (like hepatitis B or C) or other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This study tests a pill called zanubrutinib as a follow-up treatment for people with DLBCL (a type of blood cancer) who are too frail or older to receive more intensive chemotherapy but whose cancer has already shrunk after initial treatment. The goal is to see if this maintenance therapy helps keep the cancer in remission and improves outcomes.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.